-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Ushers in a New Chapter of High-Quality Development
Category:
发布时间：2024-01-02
【概要描述】
At a pivotal moment, we are charting a new chapter of high-quality development, with full-year operations poised to reach yet another record high and our ranking among China’s Top 100 Pharmaceutical Companies accelerating. Within our laboratories and production facilities, a vibrant spirit of innovation is forging new momentum for relentless progress, as new forms of productive forces rapidly grow and strengthen. On the front lines of marketing, vigorous strides are generating an inspiring, soaring momentum, further smoothing the flow of the dual-circulation strategy. We are striving ever higher, embracing innovation, and riding the tide—steadily advancing high-quality development.
A confluence of favorable conditions is ushering in a new chapter of high-quality development, with full-year operations poised to reach yet another all-time high and the company accelerating its climb in the Top 100 Chinese Pharmaceutical Manufacturers ranking.
In the laboratory and workshop, a vibrant spirit of innovation is forging new momentum for relentless progress, accelerating the growth and strengthening of new-quality productive forces.
On the front lines of marketing, vigorous strides are forging an inspiring momentum, accelerating the smooth flow of the dual-circulation strategy.
Striving for greater heights, embracing innovation, and staying attuned to emerging trends, high-quality development is being steadily advanced.
This year, the foundation for stability has been further strengthened. Despite a complex and challenging pharmaceutical market environment, the Group has remained at the forefront of the industry, laying a solid groundwork for achieving its full-year targets.
This year, the momentum for progress has grown even stronger. Development has been substantive, with continuous gains in competitive advantage and proactive initiative through structural adjustment and transformation and upgrading; the underlying foundation of development is robust, with the advantages of innovation increasingly taking root in people’s minds; and the potential for future growth is substantial, as endogenous driving forces continue to strengthen.
Through one vivid scene after another, the tenacious and ever-changing vitality of Sihua Pharmaceutical continues to drive the company toward both qualitative improvements in effectiveness and rapid quantitative growth.
The “Three Zeros, Five Leads, Seven Focuses” Management Approach Is Starting to Yield Results
In 2023, the Group entered a critical phase of transformation and development. To align with the enterprise’s requirements for innovative, high-quality growth, Qu Jiguang, Chairman of the Board, proposed extensive and in-depth study, publicity, and promotion of the “Three Zeros, Five Leads, Seven Focuses” management philosophy and methodology. Over the past year since its implementation, this management approach has gradually taken root and is beginning to yield tangible results.
To ensure that managers at all levels fully grasp and internalize the essence of the “Three Zeros, Five Leads, Seven Focuses” management philosophy, the Group’s Party and Mass Work Department and Human Resources Department have proactively organized the development of a study syllabus, produced training videos, launched a “cloud classroom” platform, and engaged management experts. Drawing on real-world corporate management practices, they have centrally organized comprehensive, multi-dimensional, systematic briefings for mid- and senior-level managers and business personnel on the construction of an efficient “Three Zeros, Five Leads, Seven Focuses” management and operations system. After nearly a year of learning and practical application, the core project-based management approach has been widely adopted, providing strong guidance for achieving new improvements in the Group’s operations and management.
88 New Products Approved
At the end of October 2023, the Group’s application for aminophylline injection (10 mL: 0.25 g and 20 mL: 0.5 g) was approved by the National Medical Products Administration for drug manufacturing registration and is deemed to have passed the consistency evaluation. In October alone, the Group secured approval for 10 dosage forms across 8 product varieties and for 1 active pharmaceutical ingredient, demonstrating that its sustained investment in R&D has now entered a concentrated “harvest period” of innovative development.
Since the beginning of this year, the Group has secured approval for 88 new products—more than double the number of innovative achievements in 2022. Notably, stipegol dry suspension and its active pharmaceutical ingredient, as well as pentoxifylline extended-release tablets, were the first of their kind to receive regulatory approval in China. The rapid emergence of these new products has laid a solid foundation for optimizing the product portfolio, enhancing market accessibility, and effectively participating in national and regional centralized procurement initiatives. The Group’s robust pipeline of new-product applications and approvals places it among the leaders in the industry nationwide, while its increasingly diverse portfolio of innovations is powerfully driving corporate transformation and upgrading and elevating the value chain.
Nine varieties across 12 specifications have won bids in the national centralized procurement.
On December 1, the Group’s Class 4 chemical drug—Tedesozamibe Phosphate Tablets (200 mg)—received manufacturing registration approval from the National Medical Products Administration, which is deemed equivalent to passing the bioequivalence evaluation. To date, a total of 67 drug varieties comprising 87 dosage forms have either passed or been deemed to have passed the bioequivalence evaluation, primarily covering therapeutic agents for infectious diseases, the blood and hematopoietic systems, the nervous system, and the cardiovascular system. Among these, 15 dosage forms were the first in China to pass the evaluation, with Ketoprofen Sustained-Release Tablets and Stiripentol Dry Suspension being the earliest to do so, placing the Group at the forefront of the industry in generic drug bioequivalence assessment.
In the highly anticipated eighth and ninth rounds of national centralized drug procurement, the Group secured winning bids for 12 specifications across 9 product varieties, firmly establishing itself as a true “winner” in these procurement initiatives. To date, the Group has secured inclusion in the national centralized procurement program for a total of 17 product varieties, including 12 injectable formulations and 5 oral dosage forms, which has positively boosted regional sales and supported the company’s long-term development, further consolidating its operational advantages.
Eight Universities Enter into Strategic Partnerships with the Group
To establish and refine stable off-campus internship and practical training bases and to fully implement the mechanism for joint talent cultivation between universities and the Group, the Group signed a strategic cooperation agreement with Hebei Normal University on July 18.
In 2023, with a focus on advancing “Made in China” pharmaceuticals, the Group placed great emphasis on integrating industry and education. It identified key areas of alignment and leverage in research projects, technology transfer, and joint talent development, and actively forged strategic partnerships with relevant universities to drive new achievements and breakthroughs through mutually beneficial collaboration between academia and industry. To date, the Group has established innovative cooperation models and built diversified platforms with eight leading institutions, including Hebei Normal University, Lanzhou University, North China University of Science and Technology, and Qingdao University of Science and Technology. Together, these partners are engaging in in-depth, pragmatic cooperation across critical scientific and technological challenges, high-end talent cultivation, commercialization of research outcomes, and internship and employment opportunities, thereby fostering win-win outcomes for both academic and industrial stakeholders.
A smart, digital infusion workshop with a capacity of 600 million bags has been completed.
In 2023, the Group firmly embraced the “projects-first” philosophy, leveraging high-end, high-quality projects to underpin high-quality development and striving to convert its advantages in innovation into competitive advantages in industrial development.
The Group aims to build “Lighthouse Factories,” aligning with Industry 4.0 and China’s Made in China 2025 initiative to address weaknesses, strengthen core competencies, and solidify foundational capabilities. By integrating automated, information-driven, and intelligent equipment and technologies into industrialization projects, the Group is accelerating the transformation of traditional manufacturing toward smart manufacturing. A multi-hundred-million-yuan investment has been made to construct an intelligent, digital, upright soft-bag infusion production workshop in the Shijiazhuang Economic and Technological Development Zone, benchmarked against world-class standards. The entire facility adopts the latest international integrated design philosophy and leverages cutting-edge automation, digitalization, and intelligent systems, along with IoT technologies, to achieve a significant leap in smart manufacturing capabilities. With an annual capacity of 600 million bottles (or bags), this production line will become one of the most competitive in China’s industry today.
Seventy-Five Years of Witnessing the Group’s Metamorphosis and Leap Forward
Seventy-five years of weathering storms and braving hardships have forged remarkable achievements through relentless striving. On December 2, the Group held a grand gala to celebrate the 75th anniversary of its founding, themed “A Gathering to Mark the 75th Anniversary: Joining Hands to Embark on a New Journey.”
Entering a new era, the Group has aligned itself with national development strategies and market demands, strategically integrating innovation along the industrial value chain. Committed to the research, development, and production of high-quality “Made-in-China” pharmaceuticals, the Group has steadily accumulated and leveraged its innovative achievements, ushering in a new phase of iterative product development that encompasses specialty and high-end complex generic drugs, innovative medicines, improved new drugs, active pharmaceutical ingredients, biologics, and pharmaceutical packaging materials. This has accelerated the Group’s growth trajectory, significantly enhancing its scale, innovation capacity, brand strength, and market influence. As a result, the Company has successfully transformed from a business previously dominated by a single injectable product to a diversified, multi-faceted industrial player, earning recognition as a National High-Tech Enterprise, a National Demonstration Enterprise for Technological Innovation, a Top Industrial Enterprise in China for Pharmaceutical R&D Product Lines, and a National Quality Benchmark Enterprise—thus securing a place among China’s most prestigious “national-level” enterprises.
One practice recognized as a national quality benchmark
In 2023, a total of 69 enterprises nationwide had their quality management practices recognized as national quality benchmarks. The Group’s submission, “The ‘21235’ Risk Management Model Based on Parameter-Based Release, Ensuring the Quality and Safety of Pharmaceuticals,” was successfully selected, making it the only pharmaceutical manufacturer in China to receive this honor this year.
The Group places paramount importance on pharmaceutical manufacturing quality and has proactively explored and established a “21235” risk management model based on parameter-based release. This model entails developing two sets of standards, leveraging one tool, institutionalizing two safeguards, strengthening three supporting pillars, and optimizing five key processes. By harnessing automated, information-driven, and intelligent quality management approaches, the Group achieves high-level, integrated, closed-loop quality management across the entire value chain—from R&D to production—while continuously enhancing its quality management system. This fosters synergistic development between quality management and technological innovation, accelerates the advancement of products and industries toward the high end of the value chain, steadily strengthens core competitiveness, and serves as a model and catalyst for the industry’s high-quality development.
1+1+5+2 Brand Building Reaps Bountiful Results
In 2023, the Group achieved remarkable success in brand building. The “Shimen SHIMEN” trademark was included in the first batch of enterprise trademarks and brands selected for the State Intellectual Property Office’s “Thousand Enterprises, Hundred Cities” initiative to enhance trademark and brand value; the “Shisiyao” trademark was recognized as a “Famous Brand of Hebei Province”; five trademarks—“Yinuoda,” “Ainuoda,” “Yiliyuan,” “Feidexin,” and the “Shisiyao” graphic mark”—were shortlisted as “Well-Known Brands of Hebei Province”; and two trademarks—“Yidawei” and “Yiweduo”—were shortlisted as “Excellent Brands of Hebei Province.”
The Group places great emphasis on the cultivation and protection of intellectual property and brands, firmly upholding a brand-driven corporate development strategy that leverages branding to propel innovation, green practices, and high-quality growth. It has established the “Shimen” trademark as its flagship brand, thereby creating a brand-building framework characterized by “one core brand supported by multiple complementary brands.” Through optimizing the industrial structure, nurturing and developing brands, and enhancing brand value, the Group has meticulously crafted a distinguished corporate image, effectively boosting overall business performance and elevating its corporate reputation. Currently, the Group holds one well-known trademark—“Shimen”—and nine premium-brand trademarks: “Shimen,” “Yinotong,” “New Concept,” “Yilitangke,” “Shuangke,” “Yibedi,” “Yirunwei,” “Yilikang,” and “Yishining.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091